# TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

> **NCT05743842** · NA · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DEVICE:** TriSalus™ TriNav™Infusion System
- **DIAGNOSTIC_TEST:** Angiogram
- **PROCEDURE:** Y90-radioembolization procedure

## Key facts

- **NCT ID:** NCT05743842
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743842, "TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05743842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*